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It is well established that implantable cardioverter defibrillator (ICD) is a life saving device
ensuring protection against life threatening ventricular arrhythmias. But there are certain
situations like a recent myocardial infarction where the standard guidelines do not
recommend the implantation of an ICD while the patient can still be at a risk of demise due
to a life threatening ventricular arrhythmia. There could also be a temporary indication for
protection while explanting an infected ICD system. The wearable cardioverter defibrillator
(WCD) is a device which comes to the rescue in such situations. In this brief review, we
discuss the historical aspects of the development of a WCD, technical aspects as well as the
clinical trial data and real world scenario of its use.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
It is well established that the implantable cardioverter defi-
brillator (ICD) is a life saving device, especially in patients with
a previous myocardial infarction and reduced ejection frac-
tion.1 But the DINAMIT study2 showed that prophylactic ICD
implantation is not useful in patients with recent myocardial
infarction. Still every clinician would have anecdotal experi-
ence of patients who have had sudden cardiac death (SCD)
after a recent myocardial infarction and VALIANT (Valsartan
in Acute Myocardial Infarction) study showed that the risk of
SCD in post myocardial infarction patients with left ventric-
ular dysfunction or heart failure is highest in the first 30 days
after the event.3 Thewearable cardioverter defibrillator (WCD)
(LifeVest, ZOLL, Pittsburgh, Pennsylvania) is a device which.
com (J. Francis).
2013, Cardiological Sociecan be used to bridge the situation when a patient is waiting
for an ICD. This could be either a patient with recent
myocardial infarction and left ventricular dysfunction within
the period of forty days when the definitive indication for ICD
is not yet established or when ICD implantation needs to be
deferred in patients with surgical contraindication (i.e. infec-
tion, vascular obstruction, treatable comorbidities). In this
review we will examine the technical details of a WCD as well
the current evidence for its clinical use since it is a relatively
new introduction.2. Historical aspects
In 1998, Angelo Auricchio and asssociates4 published the
preliminary data on the use of WCD in 15 persons who hadty of India. All rights reserved.
Fig. 1 e Components of a WCD system (Courtesy, ZOLL).
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ventricular fibrillation (VF). The WCD had four sensing elec-
trodes and three defibrillation pads integrated into garment
to be worn by the patient. The study was conducted in the
electrophysiology laboratory under conscious sedation. The
defibrillator device had a maximum capacity of 285 Joules (J)
monophasic shock. Though the device was capable of auto-
matic sensing and discharging, manual charging and dis-
charging was used in this study to demonstrate the
effectiveness of a 230 J shock to terminate an induced VT/VF
episode. A single 230 J shock was successful in all the 10 cases
in which a VF/fast VT was inducible during the study. The
arrhythmia was correctly detected in nine of the ten cases
while it was not detected in one case due to the erroneous
disconnection of the sensing electrodes at the time of
arrhythmia induction.
While the initial report was an acute evaluation of the ef-
ficacy of the WCD within the limits of an electrophysiology
laboratory, the next one evaluated the efficacy in the field.5
The WCD tested was a vest with ECG monitoring and defi-
brillator electrodes alongwith amonitor and an alarm system.
The home based interrogation device was connected to the
hospital through a modem. The WCD used had a weight of
approximately 1500 g and a maximum energy output of 285 J.
Of the 39 patients reported, six had ventricular fibrillation in
the setting of acute myocardial infarction while 17 had left
ventricular ejection fraction (LVEF) of less than 30% and 16 had
non-sustained ventricular tachycardia (NSVT). Patients were
provided two to three days in hospital training for the use of
the device and adaptation. Three of four episodes of VT/VF
were correctly identified and terminated. Two of these pa-
tients eventually received an ICD. Noteworthy, none of the
patients had an inappropriate WCD discharge, though arti-
factual alarms occurred in 15%. All NSVTs were promptly
recognized, but defibrillator discharge was withheld by the
patients.
United States Food and Drug Administration (FDA)
approval for the first WCD from Lifecor Inc. of Pittsburgh was
obtained in 2002.6 As per the FDA Consumer Magazine,
MarcheApril 2002, the device was to be worn 24 h a day,
except during bathing or showering. User had to transfer the
data to the monitoring hospital usually once a week using the
modem. FDA had on its file, data from 289 patients across the
United States and Europe. The average usage was 20 h a day
for about three months, in patients either awaiting cardiac
transplants or with a recentmyocardial infarction or coronary
artery bypass surgery, and an increased risk of sudden cardiac
death. Temporary skin rash was the only major side effect
noted.
While the original WCD was a monophasic device, a
biphasic device was tested for acute termination of VF by Reek
et al.7 The biphasic device had amaximum output of 150 J and
it could terminate induced VF at the first attempt with 70 J in
12 and with 100 J in 10 episodes tested. Thus it would provide
an adequate safety margin for defibrillation, though the au-
thors recommended programming maximum energy output
for ambulatory WCD patients.
As per the manufacturer’s website, over 100,000 patients
have been using the WCD by July 2013, with a first shock
success rate of 98%. Inappropriate shocks were less than oneper month of use and the shock event survival was 92%
(conscious on arrival at the emergency department or
remained at home). Median daily use has been 22.5 h per day.83. Technical aspects
3.1. Components of a WCD system
The WCD system has three defibrillation and 4 ECG sensing
electrodes, fitted within a garment to be worn by the patient.
The defibrillation electrodes are self gelling type and the ECG
electrodes are non-adhesive dry tantalum oxide capacitive
electrodes. The defibrillator unit is carried on a waist belt
(Figs. 1 and 2). Two ECG channels can be monitored with the
two pairs of ECG electrodes from front to back and right to left
lead sets.9 Microampere alternating current is used to check
electrode contacts as in conventional monitoring systems.3.2. Functioning of WCD system
The system uses heart rate, template matching and the event
persistence before deciding on defibrillation. There is a
sensing function to detect electrode fall off as it is used in
externally worn electrode systems. If the signal from one lead
is found to be suboptimal, the device will revert to single
channel mode, ignoring the inputs from the faulty channel. A
patient responsiveness system allows aborting of defibrilla-
tion attempt in a conscious patient. Patient responsiveness
system gives out a vibratory alarm once the arrhythmia is
detected. This is followed by a cascade of audible alarms of
increasing intensity so that the patient has the option to press
the patient response button to avert a shock. Just before
delivering the shock, the defibrillation electrodes release a gel
to reduce the electrical impedance and the device gives an
announcement for bystanders to keep off the patient. If the
patient does not respond to the alarms or the response button
is released by an unconscious patient the system delivers 5
shocks. ECG records from 30 s prior to the alarmuntil 15 s after
the alarm can be stored and sent to a secure server by modem
later. Patients can also initiate manual ECG recordings.9 If the
WCD detects an asystole, it gives an announcement to call the
ambulance so that bystanders can respond.
Fig. 2 e Typical method of applying the life vest (Courtesy,
ZOLL).
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The data from the Wearable Defibrillator Investigative Trial
(WEARIT) and Bridge to ICD in Patients at Risk of Arrhythmic
Death (BIROAD) trials on 289 patients was published in 2004.10
WEARIT enrolled 177 patients with symptomatic heart failure
and LVEF less than 30% while BIROAD Study enrolled 112 pa-
tients after myocardial infarction or coronary artery bypass
grafting (CABG) at high risk of sudden death, but not receiving
an ICD upto 4 months. The studies were designed as separate
studies, but on request of the FDA the results had to be re-
ported using the pooled data from both studies. There
occurred 8 VT/VF episodes in 6 patients, six episodes (75%)
were successfully treated with the first shock by the WCD. In
over 901 months of patient use, six inappropriate shocks
occurred (monthly rate of 0.67%). Six of the 12 deaths which
occurred during this period were sudden deaths. Of these 5
occurred when the patients were not wearing the WCD while
one occurred while the device was been worn incorrectly.
Though in general the device was well tolerated, 68 patients
stopped using it due to comfort issues or adverse reactions.5. Real world data on the use of WCD
Dillon et al9 performed a retrospective analysis of arrhythmia
detection, appropriate and inappropriate shocks over a one
year period. A total of 2105 patients wore the WCD between
January 1, 2006, and December 31. Twenty one percent used it
following an acute myocardial infarction, 10% had old
myocardial infarction, 28% cardiomyopathy and 21% used it
following ICD removal. Combined WCD usage period for all
patients was 102,583 days (3419 patient-months). The median
period of usage was 36 days (range of 3e365) and the median
daily use was 21.3 h (range of 0e23.9). The rate of appropriate
shocks was 1.58 per 100 patient-months while that of inap-
propriate shocks was 0.99 per 100 patient-months. Only 2.7%
of the arrhythmias detected lasted more than 25 s, while the
majority was self-terminating.
A post market release nationwide registry from the United
States captured the data of 3569 patients using WCD.11 The
usage period ranged from 1 to 1590 days. Average daily use ofmore than 90% of time was noted in 52% of patients and more
than 80% usage in 71% of patients respectively. Fifty nine
patients had 80 VT/VF episodes and first shock was successful
in 79 of 80 episodes (99%). This corresponds to an event rate of
20 appropriate shocks per 100 patient years. Interestingly, in
the patient in whom WCD could not terminate VT, even
multiple external shocks from the ambulance and in the
emergency department could not terminate the arrhythmia
that was finally converted pharmacologically. Eight patients
who were unconscious with VT/VF finally died even after
successful cardioversion of the arrhythmia by the WCD.
Overall survival was 99.2% (3541 of 3569 patients). Survival for
VT/VF events was 90% (72 of 80). There were 341 patients with
early post infarction left ventricular dysfunction (‘window
period’) inwhich an ICD is not recommended based on current
guidelines.12 Ten of them experienced an arrhythmic event
with appropriate WCD shocks and eight survived. Discontin-
uation of WCD use was primarily due to comfort issues (size
and weight of the device) which occurred in 14.2% of patients.5.1. Use of WCD in children
Data on the usage ofWCD in children are scarce. Everitt et al13
reported the data on four children below the age of 18 years
who used WCD during a two and a half year period at their
center. None of them had an appropriate shock, but two of
them had non compliance in usage. This lead to failure of
detection and treatment of life threatening arrhythmia in one
of them. Two patients needed down sizing to improve elec-
trode contact and sensing.
Collins and colleagues used the manufacturer’s database
for a retrospective analysis of usage in children of age 18 years
or less and compared it with data on those between the ages of
19e21 years.14 In the first group they could identify 81 pa-
tients, while there were 103 patients in the latter group. They
found no differences between the groups in the average hours
of usage per day or the total number of usage days. In the
younger patient group, there was one inappropriate therapy
and one deviceedevice interaction leading to withholding of
therapy. No patient received appropriate shocks in the
younger age group, whereas two patients had five appropriate
discharges and one patient had an inappropriate discharge in
the older group.5.2. WCD in congenital heart disease
43 patients with congenital heart disease received a WCD
between 2005 and 2010 as per the prospective nation wide
WCD registry from the United State.15 Their mean age was
38  27 years and 37% of them had LVEF less than 30%. The
indication for usage was mainly transplant listing and there
was 91% compliance in the usage ofWCD. 37%had tetralogy of
Fallot while 21% had a combination of other lesions. Solitary
lesions were present in 29%. No significant arrhythmias were
documented during the median usage of 27 days and there
were no appropriate or inappropriate shocks. There was 5%
mortality during WCD use and 8% in the one year follow up
after WCD use contributing to a total of 13% in the study
period.
Table 1 e Indications for use of WCD as per medical
order.
Indication Percentage
Recent MIa 26
Recent CABGb 9
Early NICMc 37
Class IV CHFd 2
Explants 8
Sudden cardiac arrests 16
Genetic 1
Unspecified 1
a MI: myocardial infarction.
b CABG: coronary artery bypass graft.
c NICM: non-ischemic cardiomyopathy.
d CHF: congestive heart failure.
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The indication for WCD usage in 119 patients with inherited
arrhythmias was mainly while waiting for the results of ge-
netic testing (47%) and following explantation of an ICD for
infection/malfunction (30%).15 54% of patients had long QT
syndrome, 33% had Brugada syndrome, and 8% had arrhyth-
mogenic right ventricular dysplasia (ARVD). WCD shocks
successfully corrected arrhythmias in three cases during a
median usage period of 29 days and there were 7 inappro-
priate shocks. This corresponds to event rates of 27 appro-
priate shocks per 100 patient years and 63 inappropriate
shocks per 100 patient years. Inappropriate shocks were due
to noise being detected as VT/VF. Compliance rate of wearing
WCD was 91%. There was 2% mortality during WCD usage
(one patient was not wearing the device at the time of death
and the other one died of peritonitis following colonic rupture)
and 1% in the following year.5.4. WCD in peripartum cardiomyopathy
107 women in the age group of 17e43 years used the WCD
between 2003 and 2009 for peripartum cardiomyopathy.16 Of
these 13 (12%) women used it during pregnancy, while the rest
had it after delivery. No appropriate or inappropriate shocks
were documented during an average usage of 124  123 days.
No patient died during WCD usage. Mean daily usage was
18.3  5.3 h (76.3% daily usage). Discontinuation of usage was
due to non-adherence or discomfort in 14%.6. Indications for a WCD
The WCD is designed to bridge a temporary risk of sudden
arrhythmic death until ICD implantation or when the risk can
not be determined yet (i.e. newly diagnosed cardiomyopathy
or myocarditis). Following situations can be considered as
indications for WCD use:
1. To prevent sudden arrhythmic death until the indication
for ICD implantation is clearly established as after a recent
myocardial infarction or coronary artery bypass grafting or
until significant reduction of risk had occurred.
2. Patients before or immediately after percutaneous or sur-
gical revascularization, when improvement of left ven-
tricular function can be expected.
3. Patients awaiting cardiac transplantation, as an alternative
to ICD implantation.
4. When temporary protection is needed as in patients after
explantation of an infected ICD system awaiting
reimplantation.
5. Temporary inability to implant an ICD due to comorbid
conditions.
6. Patient refusal of ICD which is clinically indicated.
7. Patients with ICD indication, who are in NYHA class IV
heart failure or have a life expectancy of less than year.
Indications for use as permedical orders available from the
manufacturer’s website8 (July 2013) is given in Table 1.7. Inappropriate WCD shocks
Just like ICDs, WCDs can also give inappropriate shocks when
actually one is not needed. The various reasons include noise
detecting in the ECG signal, supraventricular tachycardia,
pacemaker spikes, double counting due to Twave oversensing
and non-sustained VT. Of these, the most common are signal
artefacts. An inappropriate shock rate of 0.67e1.4 per 100
patient-months usage has been reported.9e11 Unlike in ICD
recipients, the patient wearing a WCD can withhold an inap-
propriate shock by pressing the patient response button
Therefore inappropriate shocks by the WCD occur only when
there is a combination of inappropriate detection and absence
of patient response. In fact the inappropriate shock rates were
five times lower than the inappropriate detection rates. The
absence of patient response could be due to various reasons
includingmental/physical inability at that time, forgetting the
training given and rarely due to not recognizing the alarm.8. Potential problems specific to WCD
Unlike ICDs, the WCD is worn externally and sensing prob-
lems can occur due to deformation of skin and movement of
the electrodes over the skin. Skin burns under the defibrilla-
tion pads have been reported rarely. Electromagnetic inter-
ference and interference from non-cardiac electrical signals
can affect the sensing function of the WCD and may cause
inappropriate shocks.9 Theoretically, external electromag-
netic influences can potentially affect theWCDmore than the
ICD due to the external location of the ECG monitoring elec-
trodes. An inappropriate shock given due to signal interfer-
ence can potentially induce ventricular fibrillation as it may
not be synchronized correctly. Though the WCD attempts to
synchronize the shock to the R wave for a period of 3 s, syn-
chronization may not be possible if there is severe interfer-
ence on the sensed ECG signal. Unsuccessful defibrillation due
to incorrect reversal of electrodes by patients in such a way
that the shocks were not directed towards the skin has
occurred in two patients.10 This problem has been resolved in
the current version of WCD which gives an alarm if the skin
contact of the defibrillation electrodes are not proper. Non-
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to a 40% decrease in size and weight of the defibrillator unit
and new chest garments. It is known that some patients may
have asystole or severe bradycardia after defibrillation for VT/
VF. As up to now, pacing capabilities are not available in the
WCD.9. DeviceeDevice interactions
LaPage MJ17 reported a fatal deviceedevice interaction be-
tween a unipolar pacemaker and a WCD. In an 18-year-old
awaiting cardiac transplantation, ventricular tachycardia was
initially detected correctly by the WCD, but the device later
reverted to non-recognition mode due to detection of large
unipolar pacing artifacts, therapy was not delivered culmi-
nating in patient demise.10. The future of WCD
Future technological advances are sure to bring down the size
and weight of the WCD further and make its use more patient
friendly. Backup bradycardia pacing would be desirable, but
will probably be difficult to achieve. Electrode noise reduction
and improvement in signal to noise ratio can bring down the
rate of inappropriate detections and shocks significantly.
WCD rental services can also enhance the usage rates by
bringing down the cost and making it more affordable even in
developing countries. Good patient education and training
will enhance the compliance rates. Clinical registries and
studies will have to define which patients will have the
greatest benefit. One of themajor questions to be addressed is,
if bridging a temporary risk after myocardial infarction or
CABG using the WCD can improve later risk-stratification for
prophylactic ICD implantation.Conflicts of interest
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